Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Atea Pharmaceuticals, Inc.”

23 pharma patents match "Atea Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 23
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 23 pharmaceutical patents matching "Atea Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

23 results for “Atea Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 12226429

    Highly active compounds against COVID-19

    Atea Pharmaceuticals, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  2. US 12084473

    β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  3. US 12006340

    Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

    Atea Pharmaceuticals, Inc. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  4. US 11975016

    2′-substituted-N6-substituted purine nucleotides for RNA virus treatment

    Atea Pharmaceuticals, Inc. · Granted May 7, 2024 · Expires May 2, 2044

    granted
  5. US 11813278

    Highly active compounds against COVID-19

    Atea Pharmaceuticals, Inc. · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted
  6. US 11738038

    Highly active compounds against COVID-19

    Atea Pharmaceuticals, Inc. · Granted Aug 29, 2023 · Expires Aug 24, 2043

    granted
  7. US 11707480

    Highly active compounds against COVID-19

    Atea Pharmaceuticals, Inc. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  8. US 11690860

    Treatment of HCV infected patients with cirrhosis

    Atea Pharmaceuticals, Inc. · Granted Jul 4, 2023 · Expires Jun 29, 2043

    granted
  9. US 10946033

    2′-substituted-N6-substituted purine nucleotides for RNA virus treatment

    Atea Pharmaceuticals, Inc. · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted
  10. US 10906928

    Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

    Atea Pharmaceuticals, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  11. US 10894804

    Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

    Atea Pharmaceuticals, Inc. · Granted Jan 19, 2021 · Expires Jan 14, 2041

    granted
  12. US 10875885

    β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Dec 29, 2020 · Expires Dec 24, 2040

    granted
  13. US 10874687

    Highly active compounds against COVID-19

    Atea Pharmaceuticals, Inc. · Granted Dec 29, 2020 · Expires Dec 24, 2040

    granted
  14. US 10870672

    β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Dec 22, 2020 · Expires Dec 17, 2040

    granted
  15. US 10870673

    β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Dec 22, 2020 · Expires Dec 17, 2040

    granted
  16. US 10815266

    β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  17. US 10711029

    Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection

    Atea Pharmaceuticals, Inc. · Granted Jul 14, 2020 · Expires Jul 9, 2040

    granted
  18. US 10519186

    Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

    Atea Pharmaceuticals, Inc. · Granted Dec 31, 2019 · Expires Dec 26, 2039

    granted
  19. US 10239911

    Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  20. US 10202412

    β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections

    Atea Pharmaceuticals, Inc. · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  21. US 10005811

    β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Jun 26, 2018 · Expires Jun 21, 2038

    granted
  22. US 10000523

    β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Jun 19, 2018 · Expires Jun 14, 2038

    granted
  23. US 9828410

    β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Nov 28, 2017 · Expires Nov 23, 2037

    granted